{"url_path":"/sec/ptix/10-q/2026/item-6","section_key":"item-6","section_title":"Item 6 Exhibits**","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-03-09","source_url":"https://www.sec.gov/Archives/edgar/data/1022899/0001493152-26-009301-index.html","accession_number":"0001493152-26-009301","cik":"0001022899","ticker":"PTIX","issuer_name":"Protagenic Therapeutics, Inc.\\new","edgar_url":"https://www.sec.gov/Archives/edgar/data/1022899/0001493152-26-009301-index.html","primary_entity_key":"0001022899","primary_entity_name":"Protagenic Therapeutics, Inc.\\new"},"word_count":223,"has_tables":true,"body_markdown":"**Item\n6. Exhibits**\n\n \n\nThe\nfollowing is a complete list of exhibits filed as part of this Form 10-Q. Exhibit numbers correspond to the numbers in the Exhibit Table\nof Item 601 of Regulation S-K.\n\n \n\n**Exhibit**\n \n**Description**\n\n \n \n \n\n31.1\n \n[Chief Executive Officer Certification as required under section 302 of the Sarbanes Oxley Act (€)](ex31-1.htm)\n\n \n \n \n\n31.2\n \n[Chief Financial Officer Certification as required under section 302 of the Sarbanes Oxley Act (€)](ex31-2.htm)\n\n \n \n \n\n32.1\n \n[Chief Executive Officer and Chief Financial Officer Certification pursuant to 18 U.S.C. section 1350 as adopted pursuant to section 906 of the Sarbanes Oxley Act *](ex32-1.htm)\n\n \n \n \n\n101.INS\n \nInline\nXBRL Instance Document (€)\n\n \n \n \n\n101.CAL\n \nInline\nXBRL Taxonomy Extension Schema Document (€)\n\n \n \n \n\n101.SCH\n \nInline\nXBRL Taxonomy Extension Calculation Linkbase Document (€)\n\n \n \n \n\n101.LAB\n \nInline\nXBRL Taxonomy Extension Label Linkbase Document (€)\n\n \n \n \n\n101.PRE\n \nInline\nXBRL Taxonomy Extension Presentation Linkbase Document (€)\n\n \n \n \n\n101.DEF\n \nInline\nXBRL Taxonomy Extension Definition Linkbase Document (€)\n\n \n \n \n\n104\n \nCover\nPage Interactive Data File (embedded within the Inline XBRL document)\n\n \n\n(€)\n- Filed herewith.\n\n(*)\n-Furnished, not filed, in accordance with item 601(32)(ii) of Regulation S-K.\n\n \n\n33\n\n \n\n** **\n\n**SIGNATURES**\n\n \n\nPursuant\nto the requirements of Section 12 of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on\nits behalf by the undersigned, thereunto duly authorized.\n\n \n\nMarch 9, 2026\n**Protagenic\nTherapeutics, Inc.**\n\n \n \n \n\n \nBy:\n*/s/\nAlexander K. Arrow*\n\n \n \nChief\nFinancial Officer\n\n \n\n34"}